Abstract
Researchers at Northern Illinois University and Ohio University have developed a new class of platinum complexes that exhibit anticancer activity without binding to DNA. They suggest the finding may lead to next-generation therapeutics that have fewer side effects and less potential for resistance than marketed platinum drugs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
